| Assessment Status | Rapid Review Complete |
| HTA ID | 22062 |
| Drug | Macimorelin acetate |
| Brand | Ghryvelin® |
| Indication | For the diagnosis of growth hormone deficiency (GHD) in adults. |
| Assessment Process | |
| Rapid review commissioned | 30/08/2022 |
| Rapid review completed | 04/10/2022 |
| Rapid review outcome | The NCPE recommends that macimorelin acetate (Ghryvelin®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. July 2023
